NCT04619082View on ClinicalTrials.gov

TAF to Prevent HBV Reactivation in Cancer Patients

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hepatitis B Reactivation
Interventions
DRUG

Tenofovir alafenamide

Tenofovir alafenamide 25 mg once per day for one year

Trial Locations (5)

600

Dalin Tzu Chi General Hospital, Chiayi City

Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City

St. Martin De Porress Hospital, Chiayi City

Unknown

National Taiwan University Hospital, Yun-Lin Branch, Douliu

Chi Mei Medical Hospital, Tainan City

All Listed Sponsors
collaborator

St. Martin De Porress Hospital

OTHER

collaborator

Dalin Tzu Chi General Hospital

OTHER

collaborator

National Taiwan University Hospital, Yun-Lin Branch

OTHER

collaborator

Chi Mei Medical Hospital

OTHER

lead

Chiayi Christian Hospital

OTHER